Tag Archives: Oncology
Abbott Shells Out $3.7 Billion for Piramal
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy Also tagged Abbott, branded generics, Diabetes, Eli Lilly, Emerging Markets, generics, india, Merck, Piramal Leave a comment
Astellas and OSI Come Together
The months-long saga is finally over: Astellas’ enhanced offer of $57.50 a share—around $4 billion—has finally netted it Melville, NY-based OSI Pharmaceuticals.
The Japan-based pharma first extended an acquisition offer of $52 per share ($3.5 billion) to OSI on March 1, only to be met with a resounding “Nay” from the board, which said $52 [...]
Posted in Deals, News, Strategy Also tagged Astellas, hostile takeovers, Japan, mergers, OSI, pipeline Leave a comment
Q&A with Steven Paul: Lilly’s New Development Plan
Last week, Lilly announced a major restructuring plan focused around the creation of one Developmental Center of Excellence and several individual business units. The media (Pharm Exec included) focused on the news that 5,500 jobs were being cut as part of the plan. This week, we’re talking to Lilly to find out what the company’s [...]
Posted in Strategy Also tagged Biotechnology and Pharmaceuticals, Breast cancer, business, Cancer, Clinical trial, Lilly Research Laboratories, Research and development 3 Comments

Financial Woes Affect Cancer Patients’ Treatment Decisions